PainReform (NASDAQ:PRFX) Trading 1.3% Higher – Should You Buy?

PainReform Ltd. (NASDAQ:PRFX) shares were up 1.3% on Monday . The company traded as high as $1.01 and last traded at $1.01. Approximately 49,309 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 438,878 shares. The stock had previously closed at $0.9971.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on PRFX shares. Wall Street Zen upgraded PainReform to a “sell” rating in a research note on Saturday, August 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of PainReform in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, PainReform currently has an average rating of “Sell”.

PainReform Trading Up 1.3%

The stock has a market capitalization of $878,700.00, a PE ratio of -0.00 and a beta of 1.06. The stock’s fifty day simple moving average is $1.24 and its 200-day simple moving average is $1.94.

About PainReform

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.